About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biocon-Media
  > MEDIA
  Overview
  Press Releases
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts
  
  
     
 

Company Statement

Biocon´s Clarification post media reports on “Biocon on the FDA list for not paying facility fee”

Biocon has paid Facility Fee for its API facility to USFDA in Sep 2017

Bengaluru, Karnataka, India, Dec 13, 2017:

”This is in reference to certain media reports on Biocon being on the FDA list for non-payment of facility fee. We hereby clarify that Biocon's API facility has a different FEI no. for which the facility fee to the USFDA has been paid in September 2017. We are notifying the regulator on the inadvertent error of ascribing FEI no 3003981475 to our API facility and including it in the GDUFA facility fee arrear list. Biocon accords utmost importance to compliance and has not missed payment of any regulatory fee to the USFDA “

 

- Company Spokesperson

<< Back

 

 Download Company  Statement
 
 
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved